Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GV-971 for mild to moderate Alzheimer's disease
CTR20231675Phase 4Active
- Sponsor
- Green Valley
- Start
- Oct 2023
- Modality
- Microbiome-Derived Products → Microbiome Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of sodium oligomannate in Alzheimer's disease (AD), sponsored by Green Valley. Started Oct 2023; status: active.
02
Drugs
sodium oligomannate
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on CTR20231675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231675.